Pharming Group presents its preliminary (unaudited) financial report for the first nine months ended September 30, 2021.
- Patient enrollment and product demand driving ongoing revenue recovery to US$52.9 million in Q3 2021
- Operating profit impacted by upfront payment of US$ 13.1 million for the in-licensing of OTL-105.
- Continued strong positive cash flow from operations enable increasing investment in the pipeline to support long-term growth
The company will hold an analyst call at 13:30CET/07:30ET today.Details below:
Conference call dial-in information:Thursday October, 28, 2021 13:30CET/07:30ETPlease note, the Company will only take questions from dial-in attendees.
Webcast Link:https://webcast.openbriefing.com/pharming-q321/
Dial-in details:Netherlands (Local) 085 888 7233
United Kingdom 0800 640 6441
United Kingdom (Local) 020 3936 2999
United States (Local) 1 646 664 1960
All other locations +44 20 3936 2999
Access code: 147906"I look forward to the read-out of the registration enabling study for leniolisib, expected early in the new year, as a product with transformational potential for APDS patient's lives and also transformational commercial potential for Pharming"
- Sijmen de Vries - CEOAttachments
- Original document
- Permalink
Disclaimer
Pharming Group NV published this content on 28 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 October 2021 07:50:04 UTC.